134841-10-4

Basic information

• Product Name: 2-Propenoic acid, 3-[3-(acetyloxy)-4-methoxyphenyl]-, (E)-
• CAS NO: 134841-10-4
• Molecular Formula: C12H12O5
• Molecular Weight: 236.224
• Mol File: 134841-10-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 389.2±32.0 °C(Predicted)
• Density: 1.265±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 2-Propenoic acid, 3-[3-(acetyloxy)-4-methoxyphenyl]-, (E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-[3-(acetyloxy)-4-methoxyphenyl]-, (E)-(134841-10-4)
• EPA Substance Registry System: 2-Propenoic acid, 3-[3-(acetyloxy)-4-methoxyphenyl]-, (E)-(134841-10-4)

Safety Data

• Hazardous Substances Data: 134841-10-4(Hazardous Substances Data)

Upstream product

• 537-73-5 trans-3-hydroxy-4-methoxycinnamic acid 
• 75-36-5 acetyl chloride 
• 537-73-5 isoferulic acid 
• 108-24-7 acetic anhydride 
• 141-82-2 malonic acid 
• 881-57-2 isovanillin acetate 

Downstream Products

• 1613391-25-5 (E)-N-(3-chlorophenyl)-3-(3-hydroxy-4-methoxyphenyl)-N-methyl-prop-2-enamide 
• 1613391-41-5 (E)-N-(3-chlorophenyl)-3-(3-acetoxy-4-methoxyphenyl)-N-methyl-prop-2-enamide 
• 1223568-49-7 (E)-3-(3-hydroxy-4-methoxyphenyl)-N-(1-methyl-1H-benzimidazol-2-yl)prop-2-enamide hydrochloride 
• 1223569-56-9 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-(1-methyl-1H-benzimidazol-2-yl)prop-2-enamide 
• 1223568-51-1 (E)-N-(1,3-benzoxazol-4-yl)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enamide 
• 1223568-17-9 (E)-3-(3-hydroxy-4-methoxyphenyl)-N-(1-naphthyl)prop-2-enamide 
• 1223569-25-2 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-(1-naphthyl)prop-2-enamide 
• 1613391-39-1 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-(2-naphthyl)-prop-2-enamide 
• 1223569-53-6 (E)-3-(3-acetoxy-4-methoxyphenyl)-N-indan-1-yl-acrylamide 

Relevant articles and documents

Synthesis and biological evaluation of curcuminoid derivatives

Many curcuminoid derivatives have been reported to have multiple biological activities. The aim of this study was to improve the biological activity of curcuminoids by synthesizing 16 new derivatives which combined cinnamic acids with curcuminoids, and we also analyzed the structure-activity relationship of the new compounds. Almost all the new compounds showed encouraging activity, especially compound 7g. It had much better antioxidant activity than curcuminoids and Vitamin C (VC), and also had the most significant antibacterial activity, which was 5-folder better than ampicillin (one of the best marketed antibiotics) with a minimum inhibitory concentration (MIC) of 0.5 μg/mL against Gram-positive cocci (Staphylococcus aureus and Streptococcus viridans) as well as Escherichia coli and 0.6 μg/mL against Enterobacter cloacae. Compound 7g also showed the greatest anticancer activity with a much lower IC50, which was 0.51 μM against MCF-7, 0.58 μM against HepG-2, 0.63 μM against LX-2, and 0.79 μM against 3T3. The results suggest that these compounds have promising potential as candidates for the treatment of cancer and thus further studies are warranted.

NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES

The invention relates to novel guanidine derivatives in the cinnamic series of general formula (I): The invention also relates to the process for preparing said guanidine derivatives and also to synthetic intermediates. Finally, the invention relates to t

A quantitative structure-activity relationship study of the antifungal properties of some cinnamic acid derivatives using lipophilicity (log P), second order molecular connectivity (2χ(v)) and information content (1IC)

-